GV, Alphabet Inc’s venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
Click here for original story, Alphabet’s GV leads funding in gene editing company Verve Therapeutics
Source: Reuters Science News